DLL3 and neoplasm: Low DLL3 tumor expression showed a shorter median PFS of 8 months (95%CI: 4.1–11.8 months) compared with the median PFS of the high DLL3 expression arm, which was 17 months (95%CI: 9.6–24.3 months) (p-value = 0.009).